All News
Filter News
Found 743 articles
-
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
12/19/2022
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
-
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
-
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
12/6/2022
AbbVie and HotSpot Therapeutics, Inc. today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
-
SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
-
Pediatric Clinical Trials Market Size, Growth, Trends | Report 2022-2030
12/2/2022
As per new report study, the global pediatric clinical trials market was estimated at USD 14.6 billion in 2021 and it is expected to surpass around USD 23.7 billion by 2030, poised to grow at a CAGR of 5.53% from 2022 to 2030.
-
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock - November 29, 2022
11/29/2022
Alaunos Therapeutics, Inc. announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for gross proceeds of approximately $15.7 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Alaunos.
-
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock - November 28, 2022
11/28/2022
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, announced that it has commenced an underwritten public offering of its common stock.
-
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
11/15/2022
Neutron Therapeutics and Cosylab announced that they have reached their second joint milestone in the clinical commissioning of Neutron Therapeutics' nuBeam® BNCT System, utilizing Cosylab's OncologyOne software, at Helsinki University Hospital – implementation of a complete treatment workflow on a patient model.
-
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
11/14/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the third quarter ended September 30, 2022.
-
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data on the Company's Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System
11/9/2022
Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines.
-
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
11/8/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets.
-
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
11/7/2022
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company announced a poster presentation highlighting the potential of the Company’s human neoantigen T-cell receptor platform to expand its TCR Library.
-
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
11/7/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.
-
Clinical Trial Investigative Site Network Market Size to Hit USD 12.77 BN by 2030
11/1/2022
The global clinical trial investigative site network market was valued at USD 7.51 billion in 2021 and is expected to hit around USD 12.77 billion by 2030, growing at a CAGR of 6.08% from 2022 to 2030.
-
Clinical Trial Investigative Site Network Market Size Will Attain USD 13.9 BN by 2030
11/1/2022
The Global clinical trial investigative site Network market Size accounted for USD 8.4 Billion in 2022 and is estimated to achieve a market size of USD 13.9 Billion by 2030 growing at a CAGR of 7.0% from 2022 to 2030.
-
Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022
10/31/2022
Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology taking place at the Phoenix Convention Center from Nov.
-
Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium
10/28/2022
Flare Therapeutics today presented translational insights from a retrospective advanced urothelial cancer (UC) cohort in a poster titled, “Peroxisome Proliferator-Activated Receptor Gamma (PPARG) status defines the luminal lineage in molecular profiles of advanced urothelial cancers (UC)” at the 34th EORTC-NCI-AACR Symposium.
-
Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium
10/26/2022
Flare Therapeutics today presented new preclinical data in a poster presentation.
-
If you’re hoping to ace your next biopharma interview, you should make sure you know how to answer every key interview question. To help, here are 10 common interview questions and answers.